Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atara Biotherapeutics

7.82
+0.26003.44%
Post-market: 7.820.00000.00%16:14 EDT
Volume:60.73K
Turnover:480.03K
Market Cap:45.82M
PE:-0.69
High:8.30
Open:7.75
Low:7.64
Close:7.56
Loading ...

Atara Biotherapeutics Inc: FDA Has Placed a Clinical Hold on Atara's Active Investigational New Drug (Ind) Applications

THOMSON REUTERS
·
21 Jan

Atara Biotherapeutics Inc: Screening and Enrollment of New Participants in Both Programs Have Been Paused

THOMSON REUTERS
·
21 Jan

Atara Biotherapeutics Provides Update on Clinical Programs Related to Ebvallo™ (Tabelecleucel) and ATA3219

THOMSON REUTERS
·
21 Jan

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Business Wire
·
21 Jan

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

Zacks
·
17 Jan

Atara Biotherapeutics price target lowered to $17 from $21 at Canaccord

TIPRANKS
·
17 Jan

Atara Biotherapeutics Inc : Canaccord Genuity Cuts Target Price to $17 From $21

THOMSON REUTERS
·
17 Jan

Sector Update: Health Care Stocks Rise Thursday Afternoon

MT Newswires Live
·
17 Jan

Top Midday Decliners

MT Newswires Live
·
17 Jan

Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application

GuruFocus.com
·
17 Jan

Atara Biotherapeutics Shares Tumble Amid 'Compliance Issues' Involving Manufacturing Plant for Ebvallo

MT Newswires Live
·
17 Jan

US Stocks Edge Lower; Retail Sales Increase Less Than Expected

Benzinga
·
16 Jan

Atara Biotherapeutics Shares Down 43.8% After US FDA Declines to Approve Co's Cancer Therapy

THOMSON REUTERS
·
16 Jan

FDA Rejects Atara's Request to Bring Blood Cancer Treatment to Market

Dow Jones
·
16 Jan

BUZZ-Atara Biotherapeutics slumps after FDA declines to approve cancer therapy

Reuters
·
16 Jan

Atara Biotherapeutics Shares Resume Trading, Down 45% Premarket After US FDA Declines to Approve Co's Cancer Therapy

THOMSON REUTERS
·
16 Jan

BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Reuters
·
16 Jan

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Reuters
·
16 Jan

Atara Biotherapeutics: Intends to Suspend All CAR-T Activities, Significantly Cut Expenses IF Resolution Not Reached for Funding for Programs in Q1

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Crl Did Not Identify Deficiencies Related to Clinical Efficacy or Safety Data in Bla

THOMSON REUTERS
·
16 Jan